DekaBank Deutsche Girozentrale Purchases 112,676 Shares of Becton Dickinson and Co (NYSE:BDX)

Share on StockTwits

DekaBank Deutsche Girozentrale increased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 46.5% during the 2nd quarter, Holdings Channel reports. The fund owned 355,103 shares of the medical instruments supplier’s stock after buying an additional 112,676 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Becton Dickinson and were worth $88,706,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Whittier Trust Co. lifted its holdings in shares of Becton Dickinson and by 0.6% in the 2nd quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after purchasing an additional 40 shares in the last quarter. Ropes Wealth Advisors LLC grew its stake in shares of Becton Dickinson and by 0.6% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after acquiring an additional 43 shares during the period. Ballentine Partners LLC boosted its stake in Becton Dickinson and by 2.3% in the 1st quarter. Ballentine Partners LLC now owns 2,232 shares of the medical instruments supplier’s stock worth $558,000 after purchasing an additional 50 shares during the period. Private Asset Management Inc. raised its holdings in shares of Becton Dickinson and by 2.0% during the 2nd quarter. Private Asset Management Inc. now owns 2,532 shares of the medical instruments supplier’s stock valued at $638,000 after buying an additional 50 shares in the last quarter. Finally, Community Bank & Trust Waco Texas raised its holdings in shares of Becton Dickinson and by 1.8% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 2,754 shares of the medical instruments supplier’s stock valued at $694,000 after buying an additional 50 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

BDX opened at $253.34 on Wednesday. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87. The stock has a market capitalization of $68.66 billion, a PE ratio of 23.01, a PEG ratio of 1.85 and a beta of 1.11. The company’s 50 day simple moving average is $252.03.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period in the previous year, the company posted $2.91 earnings per share. The firm’s revenue was up 1.7% on a year-over-year basis. As a group, analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

In other Becton Dickinson and news, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the sale, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James C. Lim sold 1,929 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $252.01, for a total value of $486,127.29. The disclosure for this sale can be found here. Insiders sold 24,529 shares of company stock worth $5,836,116 over the last three months. Corporate insiders own 0.12% of the company’s stock.

A number of equities analysts recently weighed in on the company. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Piper Jaffray Companies decreased their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Raymond James lifted their price target on Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. UBS Group decreased their price target on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. Finally, BMO Capital Markets decreased their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $264.27.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Coherent  PT Raised to $175.00
Coherent PT Raised to $175.00
BidaskClub Upgrades E*TRADE Financial  to Hold
BidaskClub Upgrades E*TRADE Financial to Hold
CME Group  Now Covered by Oppenheimer
CME Group Now Covered by Oppenheimer
Civista Bancshares  Upgraded to Hold at BidaskClub
Civista Bancshares Upgraded to Hold at BidaskClub
Cohu  Stock Rating Upgraded by BidaskClub
Cohu Stock Rating Upgraded by BidaskClub
Cognizant Technology Solutions  Downgraded by ValuEngine to Sell
Cognizant Technology Solutions Downgraded by ValuEngine to Sell


© 2006-2019 Ticker Report